A novel WINDOW of opportunity for young mantle cell lymphoma patients
Ibrutinib and ublituximab – a promising combination regimen for treating CLL?
How the removal of macrophages from tissue can stop or slow down the progression of CLL
An update on two trials evaluating venetoclax in subsets of CLL
The IFM 2012-03 trial: what will the next step be?